[急性髓系白血病造血干细胞移植的进展]
[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].
作者信息
Zhu X L, Huang X J, Wang Y
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):179-185. doi: 10.3760/cma.j.cn121090-20240422-00157.
Abstract
Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells. Although new drugs have emerged in recent years, the status of hematopoietic stem cell transplantation (HSCT) in AML still remains irreplaceable. This article reviews the adjustment of indications for HSCT in AML, donor selection, and updates of conditioning regimens, new prevention strategies for post-transplant relapse, new targeted drugs, immunotherapy combined with HSCT to improve the prognosis of relapsed and refractory AML, and optimization of transplantation technology for elderly AML.
摘要
急性髓系白血病（AML）是一种髓系造血干/祖细胞的恶性疾病。尽管近年来出现了新的药物，但造血干细胞移植（HSCT）在AML中的地位仍然不可替代。本文综述了AML中HSCT适应证的调整、供者选择、预处理方案的更新、移植后复发的新预防策略、新的靶向药物、免疫治疗联合HSCT改善复发/难治性AML的预后，以及老年AML移植技术的优化。
相似文献
1
[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):179-185. doi: 10.3760/cma.j.cn121090-20240422-00157.
2
Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Ann Hematol. 2020 Dec;99(12):2911-2925. doi: 10.1007/s00277-020-04283-0. Epub 2020 Oct 1.
3
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
4
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
5
Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
Transplant Cell Ther. 2021 Sep;27(9):774.e1-774.e12. doi: 10.1016/j.jtct.2021.05.024. Epub 2021 May 31.
6
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.
7
CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Ann Hematol. 2024 Jan;103(1):241-249. doi: 10.1007/s00277-023-05502-0. Epub 2023 Oct 17.
8
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.
9
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.
J Hematol Oncol. 2021 Sep 15;14(1):145. doi: 10.1186/s13045-021-01159-2.
10
Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
Bone Marrow Transplant. 2017 Nov;52(11):1504-1511. doi: 10.1038/bmt.2017.83. Epub 2017 May 15.
本文引用的文献
1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
2
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.
Bone Marrow Transplant. 2024 Jun;59(6):803-812. doi: 10.1038/s41409-024-02248-9. Epub 2024 Mar 4.
3
TP53 in MDS and AML: Biological and clinical advances.
Cancer Lett. 2024 Apr 28;588:216767. doi: 10.1016/j.canlet.2024.216767. Epub 2024 Feb 27.
4
STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2 T cells in acute myeloid leukemia.
Cancer Lett. 2024 Apr 10;587:216730. doi: 10.1016/j.canlet.2024.216730. Epub 2024 Feb 13.
5
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024 Apr;204(4):1227-1231. doi: 10.1111/bjh.19318. Epub 2024 Jan 30.
6
[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)].
Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):705-712. doi: 10.3760/cma.j.issn.0253-2727.2023.09.001.
7
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.
Signal Transduct Target Ther. 2023 Sep 14;8(1):348. doi: 10.1038/s41392-023-01614-1.
8
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol. 2023 Aug;10(8):e600-e611. doi: 10.1016/S2352-3026(23)00117-5. Epub 2023 Jul 3.
9
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
J Clin Oncol. 2023 Oct 10;41(29):4632-4642. doi: 10.1200/JCO.23.00101. Epub 2023 Jun 19.
10
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.
Zotero 插件